...Fusing IP estates The acquisition by IP Group plc (LSE:IPO) of fellow IP commercialization company Fusion IP plc... ...15 biotech or diagnostic investments, including genome sequencing play Oxford Nanopore Technologies Ltd. , while Fusion IP...
Fusion IP plc (LSE:FIP), Sheffield, U.K. Business: Other, Finance Date announced: 3/25/13 Type: Placing To be raised: £20 million ($30.5 million) Shares: 36.4 million Price: 55p Shares outstanding prior: 73.1 million Investors: Institutional investors Note:...
...University IP commercialization company Fusion IP partnered with an undisclosed pharmaceutical company to use the university's IP... ...Fusion owns the rights to all research generated from the university. Details were not disclosed. Fusion IP plc...
...against receptor activity-modifying protein 3 (RAMP3) Disease focus: Cancer Clinical status: Discovery Founded: 2007 by Fusion IP... ...collaborators: University of Sheffield Corporate partners: None Number of employees: 1 Funds raised: Undisclosed Investors: Fusion IP...
Fusion IP, which commercializes the university's IP, spun out Progenteq Ltd. (Cardiff, U.K.), The newco will develop a cartilage replacement therapy for acute knee injuries based on the university's IP covering a defined population of...
...Fusing IP estates The acquisition by IP Group plc (LSE:IPO) of fellow IP commercialization company Fusion IP plc... ...15 biotech or diagnostic investments, including genome sequencing play Oxford Nanopore Technologies Ltd. , while Fusion IP...
Fusion IP plc (LSE:FIP), Sheffield, U.K. Business: Other, Finance Date announced: 3/25/13 Type: Placing To be raised: £20 million ($30.5 million) Shares: 36.4 million Price: 55p Shares outstanding prior: 73.1 million Investors: Institutional investors Note:...
...University IP commercialization company Fusion IP partnered with an undisclosed pharmaceutical company to use the university's IP... ...Fusion owns the rights to all research generated from the university. Details were not disclosed. Fusion IP plc...
...against receptor activity-modifying protein 3 (RAMP3) Disease focus: Cancer Clinical status: Discovery Founded: 2007 by Fusion IP... ...collaborators: University of Sheffield Corporate partners: None Number of employees: 1 Funds raised: Undisclosed Investors: Fusion IP...
Fusion IP, which commercializes the university's IP, spun out Progenteq Ltd. (Cardiff, U.K.), The newco will develop a cartilage replacement therapy for acute knee injuries based on the university's IP covering a defined population of...